Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.

doi:10.1158/1078-0432.CCR-22-3394

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Jul 2023

Hwang Justin, Shi Xiaolei, Elliott Andrew, Arnoff Taylor E, McGrath Julie, Xiu Joanne, Walker Phillip, Bergom Hannah E, Day Abderrahman, Ahmed Shihab, Tape Sydney, Makovec Allison, Ali Atef, Shaker Rami M, Toye Eamon, Passow Rachel, Lozada John R, Wang Jinhua, Lou Emil, Mouw Kent W, Carneiro Benedito A, Heath Elisabeth I, McKay Rana R, Korn W Michael, Nabhan Chadi, Ryan Charles J, Antonarakis Emmanuel S

Abstract excerpt

PURPOSE: In patients with metastatic prostate cancer (mPC), ATM and BRCA2 mutations dictate differences in PARPi inhibitor response and other therapies. We interrogated the molecular features of ATM- and BRCA2-mutated mPC to explain the divergent clinical outcomes and inform future treatment decisions. EXPERIMENTAL DESIGN: We examined a novel set of 1,187 mPCs after excluding microsatellite-instable (MSI) tumors....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to BRCA2 Protein

Share to Genes, BRCA2

Share to Mutation

Share to Prostate Cancer Diagnosis and Treatment

Share to Prostate Cancer Treatment and Research

Share to Prostatic Neoplasms

Source

Open in PubMed

Identifiers

PMID: 37126020
DOI: 10.1158/1078-0432.CCR-22-3394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.PMID 37126020Read ↗

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerSemantic proximity Read ↗

Prognostic value of genomic mutations in metastatic prostate cancerSemantic proximity Read ↗

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read ↗

Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer.Semantic proximity Read ↗

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.Semantic proximity Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesSemantic proximity Read ↗

Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.Semantic proximity Read ↗

Molecular landscape of prostate cancer: Implications for current clinical trialsSemantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.Semantic proximity Read ↗

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.